According to the Zhitong Finance App, Sansheng Pharmaceutical (01530) announced its 2026 interim results. The group achieved revenue of 4,526 billion yuan, an increase of 3.91% over the previous year; profit attributable to the company's equity shareholders was 1,147 billion yuan, a decrease of 15.58% over the previous year; and the basic profit per share was 0.45 yuan.
Looking back at the first half of 2026, the Group responded positively to the policy requirements of innovation and development and continued to focus on the research and development of innovative drugs. During the reporting period, the construction of the Group's R&D system was accelerated, and the number of R&D personnel was expanded to about 840, focusing on 25 research and pipeline projects. The Group has achieved full coverage of major targets in the field of self-immunity, and has laid out next-generation technology routes such as T-cell adaptor (TCE) and in-vivocar-T; in the field of oncology, it lays out novel drug forms such as multi-specific antibodies, antibody-fusion proteins, TCE, and ADC, and has carried out forward-looking layouts through investment and cooperation in emerging modes such as RDC, gene and cell therapy. The Group focuses on AI-assisted drug research and development. It has constructed a professional model for drug development through its own data, which is applied to various aspects such as candidate molecule screening and clinical development.
In the field of commercialization, the Group's self-developed innovative drugs Excelsito® (amukitamab injection) and Xinbiao® (roxerubicin alpha injection) were successively approved for marketing in the first half of 2026, covering more patients who did not meet clinical needs; at the same time, stock drug marketing was under phased pressure brought about by medical insurance payment reforms and deepening collection, and in-hospital sales of traditional varieties fluctuated. The Group is maintaining the market position of core products through professional and compliant market entry and academic promotion work.
Looking ahead to the second half of 2026, the Group will continue to work on the three main lines of commercialization, new drug development, and foreign cooperation. At the commercial level, the focus is on promoting Excelsior®'s expert network in the field of psoriasis and promoting the iteration of the treatment plan of New Biao® at dialysis centers. Terbiao® will be promoted in collaboration with Terbiao® to build a complete product matrix for thrombocytopenia. The Group also expects more new products to be launched in the second half of 2026. At the R&D strategy level, the Group will continue to promote the development of pipeline products in the middle and late stages of clinical research around core treatment fields such as oncology, self-immunity, nephrology, metabolism and dermatology, increase capacity building for early research, enrich innovative molecular types, and speed up molecular development. At the level of external cooperation, the Group will continue to implement a dual strategy of independent research and development and global cooperation. On the one hand, it actively seeks opportunities for cooperative development with global multinational companies for self-developed pipelines, and on the other hand, it also extensively evaluates mergers and acquisitions and introduction opportunities in the field of innovative drugs to supplement pipeline assets. Based on more than 30 years of industry accumulation, the Group will continue to uphold the mission of “making innovative biopharmaceuticals within reach”, calmly respond to short-term business fluctuations, and firmly invest in long-term innovation capacity building to create lasting value for patients and shareholders.